Literature DB >> 18691549

A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression.

Pradip K Majumder1, Chiara Grisanzio, Fionnuala O'Connell, Marc Barry, Joseph M Brito, Qing Xu, Isil Guney, Raanan Berger, Paula Herman, Rachel Bikoff, Giuseppe Fedele, Won-Ki Baek, Shunyou Wang, Katharine Ellwood-Yen, Hong Wu, Charles L Sawyers, Sabina Signoretti, William C Hahn, Massimo Loda, William R Sellers.   

Abstract

Transgenic expression of activated AKT1 in the murine prostate induces prostatic intraepithelial neoplasia (PIN) that does not progress to invasive prostate cancer (CaP). In luminal epithelial cells of Akt-driven PIN, we show the concomitant induction of p27(Kip1) and senescence. Genetic ablation of p27(Kip1) led to downregulation of senescence markers and progression to cancer. In humans, p27(Kip1) and senescence markers were elevated in PIN not associated with CaP but were decreased or absent, respectively, in cancer-associated PIN and in CaP. Importantly, p27(Kip1) upregulation in mouse and human in situ lesions did not depend upon mTOR or Akt activation but was instead specifically associated with alterations in cell polarity, architecture, and adhesion molecules. These data suggest that a p27(Kip1)-driven checkpoint limits progression of PIN to CaP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18691549      PMCID: PMC2583442          DOI: 10.1016/j.ccr.2008.06.002

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  46 in total

1.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas.

Authors:  M Loda; B Cukor; S W Tam; P Lavin; M Fiorentino; G F Draetta; J M Jessup; M Pagano
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

2.  Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients.

Authors:  P L Porter; K E Malone; P J Heagerty; G M Alexander; L A Gatti; E J Firpo; J R Daling; J M Roberts
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

3.  Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma.

Authors:  S P Singh; J Lipman; H Goldman; F H Ellis; L Aizenman; M G Cangi; S Signoretti; D S Chiaur; M Pagano; M Loda
Journal:  Cancer Res       Date:  1998-04-15       Impact factor: 12.701

4.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

5.  Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma.

Authors:  C Cordon-Cardo; A Koff; M Drobnjak; P Capodieci; I Osman; S S Millard; P B Gaudin; M Fazzari; Z F Zhang; J Massague; H I Scher
Journal:  J Natl Cancer Inst       Date:  1998-09-02       Impact factor: 13.506

6.  Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells.

Authors:  A M De Marzo; A K Meeker; J I Epstein; D S Coffey
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

7.  Low p27 expression predicts poor disease-free survival in patients with prostate cancer.

Authors:  R M Yang; J Naitoh; M Murphy; H J Wang; J Phillipson; J B deKernion; M Loda; R E Reiter
Journal:  J Urol       Date:  1998-03       Impact factor: 7.450

8.  A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice.

Authors:  M L Fero; M Rivkin; M Tasch; P Porter; C E Carow; E Firpo; K Polyak; L H Tsai; V Broudy; R M Perlmutter; K Kaushansky; J M Roberts
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

9.  Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1).

Authors:  H Kiyokawa; R D Kineman; K O Manova-Todorova; V C Soares; E S Hoffman; M Ono; D Khanam; A C Hayday; L A Frohman; A Koff
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

10.  Pten is essential for embryonic development and tumour suppression.

Authors:  A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

View more
  88 in total

1.  TCEAL7 inhibition of c-Myc activity in alternative lengthening of telomeres regulates hTERT expression.

Authors:  Kyle Lafferty-Whyte; Alan Bilsland; Stacey F Hoare; Sharon Burns; Nadia Zaffaroni; Claire J Cairney; William Nicol Keith
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

Review 2.  Bypassing cellular senescence by genetic screening tools.

Authors:  Mar Vergel; Amancio Carnero
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

3.  Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors.

Authors:  Christian Hafner; Agustí Toll; Alejandro Fernández-Casado; Julie Earl; Miriam Marqués; Francesco Acquadro; Marinela Méndez-Pertuz; Miguel Urioste; Núria Malats; Julie E Burns; Margaret A Knowles; Juan C Cigudosa; Arndt Hartmann; Thomas Vogt; Michael Landthaler; Ramón M Pujol; Francisco X Real
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

4.  A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.

Authors:  Andrew J Armstrong; George J Netto; Michelle A Rudek; Susan Halabi; David P Wood; Patricia A Creel; Kelly Mundy; S Lindsay Davis; Ting Wang; Roula Albadine; Luciana Schultz; Alan W Partin; Antonio Jimeno; Helen Fedor; Phillip G Febbo; Daniel J George; Robin Gurganus; Angelo M De Marzo; Michael A Carducci
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

5.  p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase.

Authors:  Marina Zemskova; Michael B Lilly; Ying-Wei Lin; Jin H Song; Andrew S Kraft
Journal:  Mol Cancer Res       Date:  2010-07-20       Impact factor: 5.852

6.  Foxo3a transcription factor is a negative regulator of Skp2 and Skp2 SCF complex.

Authors:  J Wu; S-W Lee; X Zhang; F Han; S-Y Kwan; X Yuan; W-L Yang; Y S Jeong; A H Rezaeian; Y Gao; Y-X Zeng; H-K Lin
Journal:  Oncogene       Date:  2012-02-06       Impact factor: 9.867

7.  Myoepithelial and luminal breast cancer cells exhibit different responses to all-trans retinoic acid.

Authors:  Damián E Berardi; Carolina Flumian; Paola B Campodónico; Alejandro J Urtreger; María I Diaz Bessone; Andrea N Motter; Elisa D Bal de Kier Joffé; Eduardo F Farias; Laura B Todaro
Journal:  Cell Oncol (Dordr)       Date:  2015-06-05       Impact factor: 6.730

8.  Id4 promotes senescence and sensitivity to doxorubicin-induced apoptosis in DU145 prostate cancer cells.

Authors:  Jason P Carey; Ashley Evans Knowell; Swathi Chinaranagari; Jaideep Chaudhary
Journal:  Anticancer Res       Date:  2013-10       Impact factor: 2.480

9.  Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors.

Authors:  Weisheng Zhang; Brian B Haines; Clay Efferson; Joe Zhu; Chris Ware; Kaiko Kunii; Jennifer Tammam; Minilik Angagaw; Marlene C Hinton; Heike Keilhack; Cloud P Paweletz; Theresa Zhang; Chris Winter; Sriram Sathyanarayanan; Jonathan Cheng; Leigh Zawel; Stephen Fawell; Gary Gilliland; Pradip K Majumder
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

10.  Cryptotanshinone, a Stat3 inhibitor, suppresses colorectal cancer proliferation and growth in vitro.

Authors:  Weidong Li; Shakir M Saud; Matthew R Young; Nancy H Colburn; Baojin Hua
Journal:  Mol Cell Biochem       Date:  2015-04-26       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.